Related Experiment Video
Updated: Jun 23, 2025
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
RACGAP1 knockdown synergizes and enhances the effects of chemotherapeutics on ovarian cancer
Jun Ye1, Xiang Zhang2, Jia-Xuan Xie2
1Department of Obstetrics and Gynecology, The Fifth People's Hospital of Shanghai, Fudan University Shanghai, China.
Abstract:
Among the three most prevalent cancers affecting the female reproductive system, ovarian cancer (OV) ranks as the second most frequently diagnosed. It is important to investigate the genomic complexity of OV to develop diagnostic and therapeutic strategies. Through the utilization of bioinformatics analysis, it was determined that RacGTPase Activating Protein 1 (RACGAP1) holds significant significance in the field of OV chemotherapeutics, an aspect that has not been thoroughly explored in prior investigations. In our study, a notable increase in RACGAP1 expression was detected in ovarian cancer, demonstrating a robust association with clinicopathological features and patient prognosis. In vivo and in vitro testing revealed that RACGAP1 acts synergistically with chemotherapeutics to enhance their effects on ovarian cancer. Furthermore, an interaction between RACGAP1 and the subunit G2 of the condensin II complex, known as non-SMC condensin II complex subunit G2 (NCAPG2), has been identified. Our findings may provide new insight for improving therapeutic strategies for OV.
Insights
RacGTPase Activating Protein 1 (RACGAP1) is elevated in ovarian cancer (OV) and enhances chemotherapy effectiveness. This protein interacts with NCAPG2, offering new therapeutic strategies for OV patients.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Ovarian cancer (OV) is the second most common female reproductive cancer.
- Genomic complexity in OV necessitates novel diagnostic and therapeutic approaches.
Purpose of the Study:
- To investigate the role of RacGTPase Activating Protein 1 (RACGAP1) in ovarian cancer (OV) chemotherapeutics.
- To explore the association of RACGAP1 expression with OV clinicopathological features and prognosis.
Main Methods:
- Bioinformatics analysis to identify significant genes in OV chemotherapeutics.
- Quantitative analysis of RACGAP1 expression in OV tissues.
- In vivo and in vitro experiments to assess RACGAP1's synergistic effects with chemotherapy.
- Identification of RACGAP1 interacting proteins.
Main Results:
- RACGAP1 expression is significantly increased in ovarian cancer.
- Elevated RACGAP1 correlates with clinicopathological features and patient prognosis.
- RACGAP1 enhances the efficacy of chemotherapeutics in OV models.
- A novel interaction between RACGAP1 and non-SMC condensin II complex subunit G2 (NCAPG2) was identified.
Conclusions:
- RACGAP1 plays a crucial role in ovarian cancer progression and chemosensitivity.
- The identified RACGAP1-NCAPG2 interaction may represent a new therapeutic target.
- Findings provide a basis for developing improved therapeutic strategies for ovarian cancer.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...